Switzerland
cellvie, founded in 2018, is at the forefront of an innovative healthcare approach known as Therapeutic Mitochondria Transplantation (TMT), aiming to harness the potential of mitochondria for medical treatments. Originating from research developed by Dr. James McCully at Harvard Medical School, this Swiss-based startup is pioneering solutions for conditions like heart attacks and organ transplantation by focusing on mitochondrial augmentation and replacement.
The company operates within the Biotechnology, Health and Wellness, and Life Sciences industries, reflecting its diverse and highly specialized focus on cutting-edge medical interventions. Their last financial milestone was a $5.50M Seed Round investment completed on 06 February 2023, with significant backing from investors like Kizoo Technology Capital and Taiho Ventures. This endorsement not only highlights cellvie's potential for transformative impacts in healthcare but also underscores trust from sophisticated investors.
